Clinical trial

Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control

NCT06107153

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Insulin Glargine 100 UNT/ML Pen Injector [Lantus] Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Pioglitazone 30mg Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2023-11-01

PhasePHASE3

Conditions

Type2diabetesunresolved

Interventions

Insulin Glargine 100 UNT/ML Pen Injector [Lantus]DRUG

Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mgDRUG

Pioglitazone 30mgDRUG

Sponsors & collaborators

University of Basrahlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06107153 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.